According to a new Avon patent, several natural actives have been identified that can affect microfibril-associated glycoprotein 1 (MAGP-1) in the skin. This small, glycine-rich acidic protein is reportedly a key component of microfibrils and elastic fibers in skin.
Log in to view the full article
According to a new Avon patent, several natural actives have been identified that can affect microfibril-associated glycoprotein 1 (MAGP-1) in the skin. This small, glycine-rich acidic protein is reportedly a key component of microfibrils and elastic fibers in skin.
MAGP-1 has been found to form complexes with other microfibril proteins such as fibrillin. It provides structural support for elastic fiber formation, and is essential to vascular integrity, wound healing and proper body fat deposition.
The present invention refers to compounds and/or plant materials and extracts that stimulate its expression; Sesbania grandiflora, or vegetable hummingbird, for example, is among them.
Compositions and methods for stimulation MAGP-1 to improve the appearance of skin
U.S. Patent 9999587
Publication date: June 19, 2018
Assignee: Avon Products, Inc.
This invention relates to methods of improving the aesthetic appearance of skin by applying compounds that stimulate the expression of the extracellular matrix protein MAGP-1. This, in turn, reduces the appearance of fine lines and/or wrinkles.
Specifically named sources for said compounds include: Sesbania grandiflora, Antidesma bunius, Operculina turpethum, Ixora chinensis, Clerodendrum lindleyi, Amorphophallus campanulatus, Tiliacora triandra and Thunbergia laurifolia.
Compositions including these compounds are topically applied or delivered directly to the skin site in need. They comprise: a) a plant material, especially extracts, selected from one or more of A. bunius, O. turpethum, I. chinensis and C. lindleyi, and/or mixtures thereof; and b) a compound selected from 2-(2-benzyl-1-benzimidazoyl) acetamide analogs and an N-substituted sulfonyloxybenzylamine, and/or combinations/mixtures thereof.
The inventors note that A. bunius, O. turpethum, I. chinensis and C. linleyi and their extracts have never previously been reported for topical application to improve skin's appearance.
Patent accessed on June 22, 2018
![Fewer trips to the medspa? Lubrizol's Argireline Amplified Peptide, when applied in combination with Botulinum toxin type-A injections like Botox, can 'keep wrinkles at bay for nearly 8 weeks longer than [the injections] alone.'](https://img.cosmeticsandtoiletries.com/files/base/allured/all/image/2025/02/AdobeStock_309957760.67bf7a157bc68.png?auto=format%2Ccompress&fit=crop&h=191&q=70&w=340)
